Thursday, December 8, 2022
Home Tags PP Defence Therapeutics

PP Defence Therapeutics Related News

Defence Therapeutics applies Accum technology to cancer vaccines

Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...
Defence's successful study on the ACCUVAC-PT007 vaccine

Defence’s successful study on the ACCUVAC-PT007 vaccine

Defence Therapeutics Inc. has announced its successful study on its ACCUVAC-PT007 vaccine, which targets cervical cancer. Defence Therapeutics Inc. a Canadian biopharmaceutical company specialised in...
Defence Therapeutics applies Accum technology to cancer vaccines

Defence Therapeutics applies Accum technology to anti-cancer vaccine

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and...
Defence Therapeutics launches new AccuTOX lung cancer treatment

Defence Therapeutics launches new AccuTOX lung cancer treatment

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start...
Defence's successful study on the ACCUVAC-PT007 vaccine

Defence Therapeutics have been granted patents for their antibody-drug conjugate technology

Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no....
Enhancing treatment efficacy and antigen delivery with Accum

Enhancing treatment efficacy and antigen delivery with Accum

Defence Therapeutics outlines the potential of their innovative AccumTM technology to improve intracellular antigen delivery and ultimately enhance treatments for cancer and infectious diseases. Defence...
Defence Therapeutics have been granted patents for their anti drug conjugate technology

Accum A1-reprogrammed vaccine cured 80% of animals with pre-established lymphoma

Defence Therapeutics Inc, a Canadian biopharmaceutical company specialising in developing immune-oncology vaccines and drug delivery technologies, are pleased to report that Defence’s novel vaccine...
Defence Therapeutics applauds United States President on anti-cancer initiative

Defence Therapeutics applauds US President’s anti-cancer initiative

Defence Therapeutics Inc, a Canadian biotech company actively working on accelerating scientific discoveries an products development against cancer, congratulates US President, Joe Biden on...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells

Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells

Defence Therapeutics has announced groundbreaking news about the development of a novel anti-cancer cellular vaccine using reprogrammed mesenchymal stromal cells. Defence Therapeutics Inc., a Canadian...
Defence's successful study on the ACCUVAC-PT007 vaccine

Defence Therapeutics receives US patent for its ADC Platform Technology

In an exciting development, Defence Therapeutics has received a US patent covering its ADC Platform Technology. In the latest announcement on August 8th, 2022, Defence...
cancer cells

ACCUTOXTM effectively eliminates cancer cells by eliciting DNA damage

In a potentially monumental breakthrough in the war against cancer, Defence Therapeutics has revealed that its leading AccuTOXTM compound effectively kills cancer cells through...
cervical cancer vaccine

ACCUVAC-PTE7 cervical cancer vaccine provides complete protection

In a groundbreaking advancement in the treatment of cancer, Defence Therapeutics has revealed that the company’s AccuVAC-PTE7 cervical cancer vaccine completely protects against the...
cancer

Defence Therapeutics provides an update on its numerous anti-cancer projects

Biotechnology pioneers Defence Therapeutics outline its current research and development progress in a plethora of anti-cancer endeavours. In Q1 of 2022, Defence signed an agreement...
Defence Therapeutics: Accelerating the fight against cancer and infectious diseases

Defence Therapeutics: Accelerating the fight against cancer and infectious diseases

Defence Therapeutics outlines how it is actively looking to continue the development of its product pipeline in partnership with large pharmaceutical companies. Defence Therapeutics, a...
AccuTOXTM

Defence Therapeutics move closer to AccuTOXTM Phase I clinical trial

Defence Therapeutics has established an agreement with CATO SMS, who will advise on submitting the company’s clinical application to Health Canada to initiate a...
HPV vaccine

Defence Therapeutics’ HPV vaccine achieves a higher humoral response than Gardasil-9

Canadian biotechnology company Defence Therapeutics has revealed that its novel HPV vaccine has demonstrated a higher humoral response than the Gardasil-9 vaccine. The company’s new...
Defence Therapeutics achieves major milestone with anti-cancer molecule 

Defence Therapeutics achieves major milestone with anti-cancer molecule 

Biotechnology company Defence Therapeutics has announced the start of its final step in GLP studies on its anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited...
CRISPR

AccumTM platform greatly enhances CRISPR gene-editing technology

Defence Therapeutics has announced that its AccumTM platform can potently enhance Cas9 delivery in target cells, significantly advancing CRISPR gene-editing technology. The CRISPR technology offers...
Defence Therapeutics: changing the face of vaccines using AccumTM technology

Defence Therapeutics: changing the face of vaccines using AccumTM technology

Biotechnology specialists Defence Therapeutics are changing the face of vaccines using its AccumTM technology to enable precise delivery of proteins of pharmacological interest to...

Defence Therapeutics: Optimising drug efficacy with AccumTM technology

Health Europa is excited to introduce the latest captivating eBook from industry pioneers of the biotechnology sector, Defence Therapeutics, who comprehensively elucidate their revolutionary...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest